Remimazolam besylate - PAION

Drug Profile

Remimazolam besylate - PAION

Alternative Names: CNS 7056 (injection); CNS 7056X; CNS-7056; CNS-7056B; ONO-2745

Latest Information Update: 03 Apr 2017

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Developer PAION; Yichang Humanwell Pharmaceutical
  • Class Benzodiazepines; Hypnosedatives; Small molecules
  • Mechanism of Action GABA A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Anaesthesia; Sedation

Most Recent Events

  • 27 Mar 2017 Efficacy and adverse event data from a phase III trial in Sedation released by PAION
  • 16 Mar 2017 PAION announces intention to submit NDA to PMDA for Anaesthesia in mid 2018
  • 16 Mar 2017 PAION announces intention to submit NDA to US FDA for Sedation in mid of 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top